Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04534725




Registration number
NCT04534725
Ethics application status
Date submitted
30/08/2020
Date registered
1/09/2020

Titles & IDs
Public title
COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;
Scientific title
COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; C-SMART Study.
Secondary ID [1] 0 0
Peter Mac ID 20/135
Universal Trial Number (UTN)
Trial acronym
C-SMART
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cancer 0 0
Covid19 0 0
Respiratory Viral Infection 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Respiratory 0 0 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Interferon alfa
Treatment: Drugs - Selinexor
Treatment: Drugs - Lenzilumab

Experimental: prophylaxis - This study arm (arm 1) is evaluating the effect of interferon-alpha on the incidence of COVID-19 infection in cancer patients with no COVID-19 infection or no known COVID-19 positive contacts.

Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive daily interferon-alpha intranasal spray for 3 months while the other group will receive a daily placebo intranasal spray for 3 months.

Participants will be followed during the 3-month treatment for incidence of COVID-19 and other respiratory infections.

Experimental: Post-Exposure Prophylaxis - This study arm (arm 2) is evaluating the effect of interferon-alpha on the incidence of COVID-19 infection in cancer patients with confirmed exposure to COVID-19 virus.

Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive daily interferon-alpha intranasal spray for 7 days (at a higher dose than arm 1) while the other group will receive a daily placebo intranasal spray for 7 days

Participants will be followed for 28 days for incidence of COVID-19 and other respiratory infections.

Experimental: Moderate COVID-19 infection - This study arm (arm 3) is evaluating the effect of Selinexor on the incidence of COVID-19 infection in cancer patients with moderate COVID-19 infection.

Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive oral Selinexor 3 times a week for 2 weeks while the other group will receive oral placebo 3 times a week for 2 weeks

Participants will be followed for 60 days to assess effectiveness and safety.

Experimental: Severe COVID-19 infection - This study arm (arm 4) is evaluating the effect of Lenzilumab on the treatment of COVID-19 infection in cancer patients with severe COVID-19 infection.

Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive intravenous Lenzilumab over 24 hours while the other group will receive placebo intravenously over 24 hours.

Participants will be followed for 60 days to assess effectiveness and safety.


Treatment: Drugs: Interferon alfa
intranasal spray

Treatment: Drugs: Selinexor
oral tablet

Treatment: Drugs: Lenzilumab
intravenous infusion
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence of COVID-19 in cancer patients using interferon-alpha as prophylaxis without known positive contact with COVID-19 (COVID-19 confirmed by qPCR from respiratory swab)
Timepoint [1] 0 0
3 months from baseline.
Primary outcome [2] 0 0
incidence of any upper or lower community acquired respiratory viral infection assessed using local standard of care testing
Timepoint [2] 0 0
3 months from baseline.
Primary outcome [3] 0 0
incidence of COVID-19 when Interferon alpha is given as post-exposure prophylaxis with a known positive contact or exposure with COVID-19. COVID-19 confirmed by qPCR from respiratory swab .
Timepoint [3] 0 0
28 days from baseline
Primary outcome [4] 0 0
incidence of any upper or lower community acquired respiratory viral infection assessed using local standard of care testing
Timepoint [4] 0 0
28 days from baseline
Primary outcome [5] 0 0
incidence of death and/or need for invasive or non-invasive ventilation. assessed using medical records
Timepoint [5] 0 0
60 days from baseline
Primary outcome [6] 0 0
time to clinical improvement or discharge from hospital assessed using medical records
Timepoint [6] 0 0
28 days from baseline
Secondary outcome [1] 0 0
ARM 1: Duration of acute respiratory/ILI symptoms in case of confirmed respiratory infection during the study period. Assessed using patient symptom Diary PRO tool
Timepoint [1] 0 0
120 days from baseline
Secondary outcome [2] 0 0
ARM 1: Time to diagnosis of COVID-19 in case of confirmed COVID-19 diagnosed during the study period (days). Assessed using patient medical records
Timepoint [2] 0 0
120 days from baseline
Secondary outcome [3] 0 0
ARM 1: Time to diagnosis of other respiratory viral infection in case of confirmed other respiratory viral infection diagnosed during the study period (days). assessed using patient medical records
Timepoint [3] 0 0
120 days from baseline
Secondary outcome [4] 0 0
ARM 1: Illness severity in case of confirmed COVID-19 diagnosed during the study period using WHO clinical progression scale
Timepoint [4] 0 0
120 days from baseline
Secondary outcome [5] 0 0
ARM 1: Incidence of unplanned all-cause hospital admission during the study period. assessed using medical records
Timepoint [5] 0 0
120 days from baseline
Secondary outcome [6] 0 0
ARM 1: Incidence of unplanned infection-related hospital admission during the study period. assessed using medical records
Timepoint [6] 0 0
120 days from baseline
Secondary outcome [7] 0 0
ARM 1: Incidence of sero-conversion of SARS-CoV-2 at the end of the study period. assessed using qPCR
Timepoint [7] 0 0
120 days from baseline
Secondary outcome [8] 0 0
ARM 1: Incidence of death from any cause during the study period. assessed using patient medical records
Timepoint [8] 0 0
120 days from baseline
Secondary outcome [9] 0 0
ARM 1: Incidence of testing for COVID-19 during the study period. assessed using medical records
Timepoint [9] 0 0
120 days from baseline
Secondary outcome [10] 0 0
ARM 2 Duration of acute respiratory symptoms in case of confirmed COVID-19 diagnosed during the study period. assessed with PRO and medical records.
Timepoint [10] 0 0
28 days from baseline
Secondary outcome [11] 0 0
ARM 2: Time to diagnosis of COVID-19 in case of confirmed COVID-19 diagnosed during the study period (days). assessed using medical records
Timepoint [11] 0 0
28 days from baseline
Secondary outcome [12] 0 0
ARM 2: Illness severity in case of confirmed COVID-19 diagnosed during the study period. assessed using WHO clinical progression scale.
Timepoint [12] 0 0
28 days from baseline
Secondary outcome [13] 0 0
ARM 2: Incidence of unplanned all-cause hospital admission during the study period. assessed using medical records.
Timepoint [13] 0 0
28 days from baseline
Secondary outcome [14] 0 0
ARM 2: Incidence of unplanned infection-related hospital admission during the study period. assessed using medical records
Timepoint [14] 0 0
28 days from baseline
Secondary outcome [15] 0 0
ARM 2: Incidence of seroconversion of SARS-CoV-2 at the end of the study period. assessed using qPCR.
Timepoint [15] 0 0
28 days from baseline
Secondary outcome [16] 0 0
ARM 2: Incidence of testing for COVID-19 during the study period assessed using medical records
Timepoint [16] 0 0
28 days from baseline
Secondary outcome [17] 0 0
ARM 3: Time to clinical improvement assessed using medical records.
Timepoint [17] 0 0
60 days from baseline
Secondary outcome [18] 0 0
ARM 3: Illness severity of COVID-19, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale
Timepoint [18] 0 0
60 days from baseline
Secondary outcome [19] 0 0
ARM 3: change to clinical condition assessed with Karnofsky Performance score
Timepoint [19] 0 0
60 days from baseline
Secondary outcome [20] 0 0
ARM 3: Time to progression to severe COVID-19, defined by WHO ordinal scale
Timepoint [20] 0 0
60 days from baseline
Secondary outcome [21] 0 0
ARM 3: Time to all-cause mortality
Timepoint [21] 0 0
60 days from baseline
Secondary outcome [22] 0 0
ARM 3:Duration of hospitalisation assessed using medical records
Timepoint [22] 0 0
at discharge or day 60 whichever is sooner
Secondary outcome [23] 0 0
ARM 3: Duration of COVID-19 symptoms assessed using patient reported symptom diary.
Timepoint [23] 0 0
60 days from baseline
Secondary outcome [24] 0 0
ARM 3: Duration of oxygen supplementation (days). assessed using medical records.
Timepoint [24] 0 0
60 days from baseline
Secondary outcome [25] 0 0
ARM 3: change in nasopharyngeal SARS-CoV-2 viral load shedding (assessed via qPCR)
Timepoint [25] 0 0
60 days from baseline
Secondary outcome [26] 0 0
ARM 3: Safety and tolerability of selinexor using relevant medical records
Timepoint [26] 0 0
60 days from baseline
Secondary outcome [27] 0 0
ARM 3: incidence of changes in blood results relevant to clinical improvement assessed using medical records
Timepoint [27] 0 0
60 days from baseline
Secondary outcome [28] 0 0
ARM 4: Incidence of all cause death by day 28 and 60
Timepoint [28] 0 0
day 28 from baseline and day 60 from baseline
Secondary outcome [29] 0 0
ARM 4: Time to all-cause mortality
Timepoint [29] 0 0
any time up to 60 days from baseline
Secondary outcome [30] 0 0
ARM 4: Illness severity of COVID-19, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale
Timepoint [30] 0 0
any time up to 60 days from baseline
Secondary outcome [31] 0 0
ARM 4: Incidence of ARDS assessed using medical records
Timepoint [31] 0 0
any time up to 60 days from baseline
Secondary outcome [32] 0 0
ARM 4: incidence of HLH. assessed using medical records
Timepoint [32] 0 0
any time up to 60 days from baseline
Secondary outcome [33] 0 0
ARM 4: Duration of hospitalisation. assessed using hospital medical records.
Timepoint [33] 0 0
at discharge or by day 60 whichever is sooner
Secondary outcome [34] 0 0
ARM 4: Proportion discharged from hospital. assessed using medical records
Timepoint [34] 0 0
at discharge
Secondary outcome [35] 0 0
ARM 4: Incidence of mechanical ventilation up to day 28. assessed using medical records
Timepoint [35] 0 0
any time up day 28 from baseline
Secondary outcome [36] 0 0
ARM 4: Ventilator-free days and proportion who did not receive invasive mechanical ventilation. assessed using medical records
Timepoint [36] 0 0
any time up to 60 days from baseline
Secondary outcome [37] 0 0
ARM 4: Organ failure free days and proportion who did not develop organ failure. assessed using medical records.
Timepoint [37] 0 0
any time up to 60 days from baseline
Secondary outcome [38] 0 0
ARM 4: Incidence and duration of ICU admission. assessed using medical records
Timepoint [38] 0 0
at discharge or by day 60 from baseline.
Secondary outcome [39] 0 0
ARM 4: incidence and duration of supplemental oxygen use. assessed using medical records
Timepoint [39] 0 0
any time up to 60 days from baseline
Secondary outcome [40] 0 0
ARM 4: Time to clinical improvement defined as National Early Warning Score 2 (NEWS2) of <2 maintained for 24 hours.
Timepoint [40] 0 0
any time up to 60 days from baseline
Secondary outcome [41] 0 0
ARM 4: incidence of non-invasive ventilation. assessed using medical records
Timepoint [41] 0 0
any time up to 60 days from baseline
Secondary outcome [42] 0 0
ARM 4: number of participants alive and off oxygen at day 60. assessed using medical records.
Timepoint [42] 0 0
any time up to 60 days from baseline
Secondary outcome [43] 0 0
ARM 4: proportion of participants who had improved oxygenation for >48 hours. assessed using medical records
Timepoint [43] 0 0
any time up to 28 days from baseline
Secondary outcome [44] 0 0
ARM 4: Incidence of adverse events based on the national cancer institute CTCAE v5. Assessed using medical records
Timepoint [44] 0 0
any time up to day 28 from baseline.
Secondary outcome [45] 0 0
ARM 4: incidence of SAEs based on NCI CTCAE v5 assessed using medical records
Timepoint [45] 0 0
any time up to 28 days from baseline.
Secondary outcome [46] 0 0
ARM 4: change in nasopharyngeal SARS-CoV-2 viral load shedding. assessed using qPCR.
Timepoint [46] 0 0
any time up to day 60 from baseline

Eligibility
Key inclusion criteria
* ARM 1:

1. Age equal to or greater than 18 years old
2. Any haematological or solid tumour
3. Signed written and verbal informed consent
4. Willingness to inform the study nurse/co-ordinator of COVID-19 testing
5. Willingness to perform a self-collect nose/throat swab

ARM 2

1. Age equal to or greater than 18 years old.
2. Any haematological or solid tumour
3. Signed written and verbal informed consent
4. Have been exposed to a known COVID-19 case within the last 72 hours, defined by the current Department of Health and Human services such as household contact, 15 minutes of face to face exposure, 2 hours in close space.
5. Willingness to inform the study nurse/co-ordinator of COVID-19 testing
6. Willingness to perform a self-collect nose/throat swab

ARM 3 1. Age equal to or greater than 18 years of age. 2. Any haematological or solid tumour 3. Current or within the last 12 months received cancer related treatment such as chemotherapy, radiotherapy or targeted small molecule, cellular therapy or immune-modulating therapy 4. Signed written and verbal informed consent 5. Laboratory confirmation of SARS-CoV-2 by PCR as per local laboratory assays 6. Hospitalised 7. Symptoms of COVID-19 such as:

1. Fever equal to or greater than 38 degrees Celsius OR
2. Tachypnoea respiratory rate equal to or greater than 20 breaths/min OR
3. Pulse Oxygen saturation (SpO2) equal to or less than 94% 8. Concurrent standard of care antimicrobials, antivirals are allowed. 9. Female and male patients of child bearing potential will use highly effective contraception. In female child bearing potential participants a negative urine pregnancy test will be required.

ARM 4
1. Age equal to or greater than 18 years of age.
2. Any haematological or solid tumour
3. Current or within the last 12 months received cancer related treatment such as chemotherapy, radiotherapy or targeted small molecule, cellular therapy or immune-modulating therapy
4. Signed written and verbal informed consent by participant or proxy capable of giving consent
5. Laboratory virological confirmation of SARS-CoV-2 by PCR as per local laboratory assays and COVID-19 diagnosis prior to randomisation
6. Hospitalised but has not required mechanical ventilation
7. Pneumonia diagnosed by chest x-ray or computed tomography (CT) revealing infiltrates consistent with pneumonia and SpO2 equal to or less than 94% on room air or requires low-flow oxygen supplementation or requires high-flow oxygen supplementation or non-invasive positive pressure ventilation (NIPPV).
8. Has not participated in other clinical trials for COVID-19 using an immunomodulating monoclonal antibody or kinase inhibitor. Note that participants on dexamethasone, corticosteroids, remdesivir, convalescent plasma and/or hydroxychloroquine with or without azithromycin are not excluded from the study. Agents that have received emergency use authorization and/or are considered by the study site to be standard treatment at the institution for COVID-19 are permitted provided the agent is not an immunomodulating monoclonal antibody or kinase inhibitor. Participation in clinical trials with remdesivir or convalescent plasma is permitted provided that all other eligibility criteria are met.
9. Females of childbearing potential must have a negative serum or urine pregnancy test at screening/baseline. Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for 5 months following their last dose of study drug.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* ARM 1

1. Previous diagnosis of COVID-19 (microbiologically proven, either symptomatic or asymptomatic)
2. Have been exposed to a known COVID-19 case within the last 72 hours, defined by the current Department of Health and Human services such as household contact, 15 minutes of face to face exposure, 2 hours in close space.
3. Any contra-indication to intra-nasal IFN-a such as severe nasal bleeding requiring intervention, nasal malignancy, nasal deformity, radiotherapy to the nasopharynx and/or oropharynx
4. Pregnant or breast-feeding women, or women who wish to become pregnant during the course of the study
5. Participant unable to return for regular follow-up
6. Life expectancy of less than 4 months
7. Participant already included in another intervention study on the prevention of COVID-19
8. Currently unwell with influenza-like symptoms - if participant is found to be COVID-19 negative and becomes asymptomatic, they can be reconsidered for participation

ARM 2
1. Previous diagnosis of COVID-19 (microbiologically proven, either symptomatic or asymptomatic)
2. Any contra-indication to intra-nasal IFN-a such as severe nasal bleeding requiring intervention, nasal malignancy, nasal deformity, radiotherapy to the nasopharynx and/or oropharynx
3. Pregnant or breast-feeding women, or women who wish to become pregnant during the course of the study
4. Patient unable to return for follow-up
5. Life expectancy of less than 1 month
6. Patient already included in another intervention study on the prevention of COVID-19
7. Currently unwell with influenza-like symptoms

ARM 3
1. Unable to take oral medication
2. Any known allergic reactions to selinexor or concomitant medication-related contra-indications to selinexor.
3. Severe critical COVID-19 infection defined as:

1. Requiring invasive or non-invasive mechanical ventilation, ECMO
2. Anticipated unlikely to survive within 48 hours
4. In the opinion of the investigator and primary oncologist, participation in the study would not be in the best interests of the participant
5. Severe renal impairment defined as creatinine clearance (CrCL) < 20ml/min as calculated using the Cockcroft Gault formula
6. Severe hepatic impairment defined as aspartate transaminase (AST) or alanine transaminase (ALT) > 5 x upper limit of normal (ULN)

ARM 4

1. Invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 2. History of pulmonary alveolar proteinosis (PAP). 3. Women of childbearing potential who are pregnant or breastfeeding. 4. Known hypersensitivity to lenzilumab or any of its components. 5 .Use of any FDA-approved anti-IL-6 therapy (eg. tocilizumab, sarilumab, siltukimab), anti-IL-1 therapy (eg. anakinra, canakinumab) or kinase inhibitor (eg.baracitinib, ibrutinib, acalabrutinib) therapy to treat COVID-19 within 8 weeks prior to randomization. Any live vaccine within 8 weeks prior to randomisation. Note that subjects receiving other FDA-approved immunomodulators to treat underlying autoimmune disorders such as rheumatoid arthritis, psoriasis, ankylosing spondylitis, asthma, chronic obstructive pulmonary disease, atopic dermatitis, multiple sclerosis, etc. would not be excluded. Participants on corticosteroids or dexamethasone are not excluded from the study. Note: Participants on convalescent plasma, remdesivir and/or hydroxychloroquine with or without azithromycin are not excluded from the study.

6. Use of GM-CSF agents (e.g., sargramostim) within 8 weeks prior to randomisation.

7. Expected survival < 24h in the opinion of the investigator. 8. Any condition that, in the opinion of the investigator, is likely to interfere with the safety and efficacy of the study treatment or puts the subject at unacceptably high risk from the study.

9. Participation in another interventional study of COVID-19

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
17/12/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
19/04/2023
Sample size
Target
Accrual to date
Final
441
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Westmead Hospital - Westmead
Recruitment hospital [2] 0 0
St Vincent's Hospital - Fitzroy
Recruitment hospital [3] 0 0
Peter MacCallum Cancer Centre - Melbourne
Recruitment hospital [4] 0 0
Royal Melbourne Hospital - Melbourne
Recruitment hospital [5] 0 0
Austin Health - Melbourne
Recruitment postcode(s) [1] 0 0
2145 - Westmead
Recruitment postcode(s) [2] 0 0
3065 - Fitzroy
Recruitment postcode(s) [3] 0 0
3000 - Melbourne
Recruitment postcode(s) [4] 0 0
3052 - Melbourne
Recruitment postcode(s) [5] 0 0
3084 - Melbourne

Funding & Sponsors
Primary sponsor type
Other
Name
Peter MacCallum Cancer Centre, Australia
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT04534725